Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study
Interleukin-22 (IL-22) has beneficial effects on body weight, insulin resistance and inflammation in different mouse models, but its relevance for the development of type 2 diabetes in humans is unknown. We aimed to identify correlates of serum IL-22 levels and to test the hypothesis that higher IL-...
Gespeichert in:
| Veröffentlicht in: | Cardiovascular Diabetology 2017-01, Vol.16 (1), p.17, Article 17 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 17 |
| container_title | Cardiovascular Diabetology |
| container_volume | 16 |
| creator | Herder, Christian Kannenberg, Julia M Carstensen-Kirberg, Maren Huth, Cornelia Meisinger, Christa Koenig, Wolfgang Peters, Annette Rathmann, Wolfgang Roden, Michael Thorand, Barbara |
| description | Interleukin-22 (IL-22) has beneficial effects on body weight, insulin resistance and inflammation in different mouse models, but its relevance for the development of type 2 diabetes in humans is unknown. We aimed to identify correlates of serum IL-22 levels and to test the hypothesis that higher IL-22 levels are associated with lower diabetes incidence.
Cross-sectional associations between serum IL-22, cardiometabolic risk factors and glucose tolerance status were investigated in 1107 persons of the population-based KORA F4 study. The prospective association between serum IL-22 and incident type 2 diabetes was assessed in 504 initially non-diabetic study participants in both the KORA F4 study and its 7-year follow-up examination KORA FF4, 76 of whom developed diabetes.
Male sex, current smoking, lower HDL cholesterol, lower estimated glomerular filtration rate and higher serum interleukin-1 receptor antagonist were associated with higher IL-22 levels after adjustment for confounders (all P |
| doi_str_mv | 10.1186/s12933-017-0498-6 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5282888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A480548092</galeid><sourcerecordid>A480548092</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-d7a67335172768b1742ed7b67ffce2e92d460f31d8fce3976f709767fd04f5a13</originalsourceid><addsrcrecordid>eNpVUV1rHSEUlNLSpGl_QF-K0Nds4teq24fCJfS2pYFAP57F1WNqsrveqhu4_76Gm4YUOXrUmWF0EHpLyRmlWp4XygbOO0JVR8SgO_kMHVOh-o5pQZ4_6Y_Qq1JuSANqSV-iI6ap4ELTYzT9gLzOeII7mApOAcelQp5gvY1Lx9gpdjb7mGaodkxTdDjHcouDdTXlgu3iG8FFD0vFdb8DzLCPdoQK5QP-dvV9g7fifLsVuNTV71-jF8FOBd48rCfo1_bTz4sv3eXV568Xm8vOiUHUzisrFec9VUxJPVIlGHg1ShWCAwYD80KSwKnXbc8HJYMibVbBExF6S_kJ-njQ3a3jDN41d9lOZpfjbPPeJBvN_zdL_G2u053pmWZa6ybw_kEgpz8rlGpu0pqX5tm0fxda9INQDXV2QF3bCUxcQmpirg0Pc3RpgRDb-UZo0rcaWCPQA8HlVEqG8GiJEnOfqDkkalpQ5j5RIxvn3dO3PDL-Rcj_AnUPm4k</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1864845947</pqid></control><display><type>article</type><title>Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study</title><source>MEDLINE</source><source>Springer Online Journals Complete</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><creator>Herder, Christian ; Kannenberg, Julia M ; Carstensen-Kirberg, Maren ; Huth, Cornelia ; Meisinger, Christa ; Koenig, Wolfgang ; Peters, Annette ; Rathmann, Wolfgang ; Roden, Michael ; Thorand, Barbara</creator><creatorcontrib>Herder, Christian ; Kannenberg, Julia M ; Carstensen-Kirberg, Maren ; Huth, Cornelia ; Meisinger, Christa ; Koenig, Wolfgang ; Peters, Annette ; Rathmann, Wolfgang ; Roden, Michael ; Thorand, Barbara</creatorcontrib><description>Interleukin-22 (IL-22) has beneficial effects on body weight, insulin resistance and inflammation in different mouse models, but its relevance for the development of type 2 diabetes in humans is unknown. We aimed to identify correlates of serum IL-22 levels and to test the hypothesis that higher IL-22 levels are associated with lower diabetes incidence.
Cross-sectional associations between serum IL-22, cardiometabolic risk factors and glucose tolerance status were investigated in 1107 persons of the population-based KORA F4 study. The prospective association between serum IL-22 and incident type 2 diabetes was assessed in 504 initially non-diabetic study participants in both the KORA F4 study and its 7-year follow-up examination KORA FF4, 76 of whom developed diabetes.
Male sex, current smoking, lower HDL cholesterol, lower estimated glomerular filtration rate and higher serum interleukin-1 receptor antagonist were associated with higher IL-22 levels after adjustment for confounders (all P < 0.05). Serum IL-22 showed no associations with glucose tolerance status, prediabetes or type 2 diabetes. Baseline serum IL-22 levels (median, 25th/75th percentiles) for incident type 2 diabetes cases and non-cases were 6.28 (1.95; 12.35) and 6.45 (1.95; 11.80) pg/ml, respectively (age and sex-adjusted P = 0.744). The age and sex-adjusted OR (95% CI) per doubling of IL-22 for incident type 2 diabetes of 1.02 (0.85; 1.23) was almost unchanged after consideration of further confounders.
High serum levels of IL-22 were positively rather than inversely associated with several cardiometabolic risk factors. However, these associations did not translate into an increased risk for type 2 diabetes. Thus, our data argue against the utility of IL-22 as biomarker for prevalent or incident type 2 diabetes in humans, but identify potential determinants of IL-22 levels which merits further research in the context of cardiovascular diseases.</description><identifier>ISSN: 1475-2840</identifier><identifier>EISSN: 1475-2840</identifier><identifier>DOI: 10.1186/s12933-017-0498-6</identifier><identifier>PMID: 28143481</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Aged ; Biomarkers - blood ; Cardiovascular Diseases - blood ; Cardiovascular Diseases - diagnosis ; Cardiovascular Diseases - epidemiology ; Cardiovascular Diseases - prevention & control ; Complications and side effects ; Cross-Sectional Studies ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - diagnosis ; Diabetes Mellitus, Type 2 - epidemiology ; Diabetes Mellitus, Type 2 - prevention & control ; Female ; Germany - epidemiology ; Health aspects ; Humans ; Incidence ; Inflammation ; Interleukin-22 ; Interleukins ; Interleukins - blood ; Linear Models ; Male ; Metabolic Syndrome - blood ; Metabolic Syndrome - diagnosis ; Metabolic Syndrome - epidemiology ; Metabolic Syndrome - prevention & control ; Middle Aged ; Multivariate Analysis ; Odds Ratio ; Original Investigation ; Prognosis ; Prospective Studies ; Protective Factors ; Risk Assessment ; Risk Factors ; Time Factors ; Type 2 diabetes ; Up-Regulation</subject><ispartof>Cardiovascular Diabetology, 2017-01, Vol.16 (1), p.17, Article 17</ispartof><rights>COPYRIGHT 2017 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2017</rights><rights>The Author(s) 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-d7a67335172768b1742ed7b67ffce2e92d460f31d8fce3976f709767fd04f5a13</citedby><cites>FETCH-LOGICAL-c494t-d7a67335172768b1742ed7b67ffce2e92d460f31d8fce3976f709767fd04f5a13</cites><orcidid>0000-0002-2050-093X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282888/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282888/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28143481$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Herder, Christian</creatorcontrib><creatorcontrib>Kannenberg, Julia M</creatorcontrib><creatorcontrib>Carstensen-Kirberg, Maren</creatorcontrib><creatorcontrib>Huth, Cornelia</creatorcontrib><creatorcontrib>Meisinger, Christa</creatorcontrib><creatorcontrib>Koenig, Wolfgang</creatorcontrib><creatorcontrib>Peters, Annette</creatorcontrib><creatorcontrib>Rathmann, Wolfgang</creatorcontrib><creatorcontrib>Roden, Michael</creatorcontrib><creatorcontrib>Thorand, Barbara</creatorcontrib><title>Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study</title><title>Cardiovascular Diabetology</title><addtitle>Cardiovasc Diabetol</addtitle><description>Interleukin-22 (IL-22) has beneficial effects on body weight, insulin resistance and inflammation in different mouse models, but its relevance for the development of type 2 diabetes in humans is unknown. We aimed to identify correlates of serum IL-22 levels and to test the hypothesis that higher IL-22 levels are associated with lower diabetes incidence.
Cross-sectional associations between serum IL-22, cardiometabolic risk factors and glucose tolerance status were investigated in 1107 persons of the population-based KORA F4 study. The prospective association between serum IL-22 and incident type 2 diabetes was assessed in 504 initially non-diabetic study participants in both the KORA F4 study and its 7-year follow-up examination KORA FF4, 76 of whom developed diabetes.
Male sex, current smoking, lower HDL cholesterol, lower estimated glomerular filtration rate and higher serum interleukin-1 receptor antagonist were associated with higher IL-22 levels after adjustment for confounders (all P < 0.05). Serum IL-22 showed no associations with glucose tolerance status, prediabetes or type 2 diabetes. Baseline serum IL-22 levels (median, 25th/75th percentiles) for incident type 2 diabetes cases and non-cases were 6.28 (1.95; 12.35) and 6.45 (1.95; 11.80) pg/ml, respectively (age and sex-adjusted P = 0.744). The age and sex-adjusted OR (95% CI) per doubling of IL-22 for incident type 2 diabetes of 1.02 (0.85; 1.23) was almost unchanged after consideration of further confounders.
High serum levels of IL-22 were positively rather than inversely associated with several cardiometabolic risk factors. However, these associations did not translate into an increased risk for type 2 diabetes. Thus, our data argue against the utility of IL-22 as biomarker for prevalent or incident type 2 diabetes in humans, but identify potential determinants of IL-22 levels which merits further research in the context of cardiovascular diseases.</description><subject>Aged</subject><subject>Biomarkers - blood</subject><subject>Cardiovascular Diseases - blood</subject><subject>Cardiovascular Diseases - diagnosis</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Complications and side effects</subject><subject>Cross-Sectional Studies</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - diagnosis</subject><subject>Diabetes Mellitus, Type 2 - epidemiology</subject><subject>Diabetes Mellitus, Type 2 - prevention & control</subject><subject>Female</subject><subject>Germany - epidemiology</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Incidence</subject><subject>Inflammation</subject><subject>Interleukin-22</subject><subject>Interleukins</subject><subject>Interleukins - blood</subject><subject>Linear Models</subject><subject>Male</subject><subject>Metabolic Syndrome - blood</subject><subject>Metabolic Syndrome - diagnosis</subject><subject>Metabolic Syndrome - epidemiology</subject><subject>Metabolic Syndrome - prevention & control</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Odds Ratio</subject><subject>Original Investigation</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Protective Factors</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Time Factors</subject><subject>Type 2 diabetes</subject><subject>Up-Regulation</subject><issn>1475-2840</issn><issn>1475-2840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpVUV1rHSEUlNLSpGl_QF-K0Nds4teq24fCJfS2pYFAP57F1WNqsrveqhu4_76Gm4YUOXrUmWF0EHpLyRmlWp4XygbOO0JVR8SgO_kMHVOh-o5pQZ4_6Y_Qq1JuSANqSV-iI6ap4ELTYzT9gLzOeII7mApOAcelQp5gvY1Lx9gpdjb7mGaodkxTdDjHcouDdTXlgu3iG8FFD0vFdb8DzLCPdoQK5QP-dvV9g7fifLsVuNTV71-jF8FOBd48rCfo1_bTz4sv3eXV568Xm8vOiUHUzisrFec9VUxJPVIlGHg1ShWCAwYD80KSwKnXbc8HJYMibVbBExF6S_kJ-njQ3a3jDN41d9lOZpfjbPPeJBvN_zdL_G2u053pmWZa6ybw_kEgpz8rlGpu0pqX5tm0fxda9INQDXV2QF3bCUxcQmpirg0Pc3RpgRDb-UZo0rcaWCPQA8HlVEqG8GiJEnOfqDkkalpQ5j5RIxvn3dO3PDL-Rcj_AnUPm4k</recordid><startdate>20170131</startdate><enddate>20170131</enddate><creator>Herder, Christian</creator><creator>Kannenberg, Julia M</creator><creator>Carstensen-Kirberg, Maren</creator><creator>Huth, Cornelia</creator><creator>Meisinger, Christa</creator><creator>Koenig, Wolfgang</creator><creator>Peters, Annette</creator><creator>Rathmann, Wolfgang</creator><creator>Roden, Michael</creator><creator>Thorand, Barbara</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2050-093X</orcidid></search><sort><creationdate>20170131</creationdate><title>Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study</title><author>Herder, Christian ; Kannenberg, Julia M ; Carstensen-Kirberg, Maren ; Huth, Cornelia ; Meisinger, Christa ; Koenig, Wolfgang ; Peters, Annette ; Rathmann, Wolfgang ; Roden, Michael ; Thorand, Barbara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-d7a67335172768b1742ed7b67ffce2e92d460f31d8fce3976f709767fd04f5a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Biomarkers - blood</topic><topic>Cardiovascular Diseases - blood</topic><topic>Cardiovascular Diseases - diagnosis</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Complications and side effects</topic><topic>Cross-Sectional Studies</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - diagnosis</topic><topic>Diabetes Mellitus, Type 2 - epidemiology</topic><topic>Diabetes Mellitus, Type 2 - prevention & control</topic><topic>Female</topic><topic>Germany - epidemiology</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Incidence</topic><topic>Inflammation</topic><topic>Interleukin-22</topic><topic>Interleukins</topic><topic>Interleukins - blood</topic><topic>Linear Models</topic><topic>Male</topic><topic>Metabolic Syndrome - blood</topic><topic>Metabolic Syndrome - diagnosis</topic><topic>Metabolic Syndrome - epidemiology</topic><topic>Metabolic Syndrome - prevention & control</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Odds Ratio</topic><topic>Original Investigation</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Protective Factors</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Time Factors</topic><topic>Type 2 diabetes</topic><topic>Up-Regulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Herder, Christian</creatorcontrib><creatorcontrib>Kannenberg, Julia M</creatorcontrib><creatorcontrib>Carstensen-Kirberg, Maren</creatorcontrib><creatorcontrib>Huth, Cornelia</creatorcontrib><creatorcontrib>Meisinger, Christa</creatorcontrib><creatorcontrib>Koenig, Wolfgang</creatorcontrib><creatorcontrib>Peters, Annette</creatorcontrib><creatorcontrib>Rathmann, Wolfgang</creatorcontrib><creatorcontrib>Roden, Michael</creatorcontrib><creatorcontrib>Thorand, Barbara</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cardiovascular Diabetology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Herder, Christian</au><au>Kannenberg, Julia M</au><au>Carstensen-Kirberg, Maren</au><au>Huth, Cornelia</au><au>Meisinger, Christa</au><au>Koenig, Wolfgang</au><au>Peters, Annette</au><au>Rathmann, Wolfgang</au><au>Roden, Michael</au><au>Thorand, Barbara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study</atitle><jtitle>Cardiovascular Diabetology</jtitle><addtitle>Cardiovasc Diabetol</addtitle><date>2017-01-31</date><risdate>2017</risdate><volume>16</volume><issue>1</issue><spage>17</spage><pages>17-</pages><artnum>17</artnum><issn>1475-2840</issn><eissn>1475-2840</eissn><abstract>Interleukin-22 (IL-22) has beneficial effects on body weight, insulin resistance and inflammation in different mouse models, but its relevance for the development of type 2 diabetes in humans is unknown. We aimed to identify correlates of serum IL-22 levels and to test the hypothesis that higher IL-22 levels are associated with lower diabetes incidence.
Cross-sectional associations between serum IL-22, cardiometabolic risk factors and glucose tolerance status were investigated in 1107 persons of the population-based KORA F4 study. The prospective association between serum IL-22 and incident type 2 diabetes was assessed in 504 initially non-diabetic study participants in both the KORA F4 study and its 7-year follow-up examination KORA FF4, 76 of whom developed diabetes.
Male sex, current smoking, lower HDL cholesterol, lower estimated glomerular filtration rate and higher serum interleukin-1 receptor antagonist were associated with higher IL-22 levels after adjustment for confounders (all P < 0.05). Serum IL-22 showed no associations with glucose tolerance status, prediabetes or type 2 diabetes. Baseline serum IL-22 levels (median, 25th/75th percentiles) for incident type 2 diabetes cases and non-cases were 6.28 (1.95; 12.35) and 6.45 (1.95; 11.80) pg/ml, respectively (age and sex-adjusted P = 0.744). The age and sex-adjusted OR (95% CI) per doubling of IL-22 for incident type 2 diabetes of 1.02 (0.85; 1.23) was almost unchanged after consideration of further confounders.
High serum levels of IL-22 were positively rather than inversely associated with several cardiometabolic risk factors. However, these associations did not translate into an increased risk for type 2 diabetes. Thus, our data argue against the utility of IL-22 as biomarker for prevalent or incident type 2 diabetes in humans, but identify potential determinants of IL-22 levels which merits further research in the context of cardiovascular diseases.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>28143481</pmid><doi>10.1186/s12933-017-0498-6</doi><orcidid>https://orcid.org/0000-0002-2050-093X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1475-2840 |
| ispartof | Cardiovascular Diabetology, 2017-01, Vol.16 (1), p.17, Article 17 |
| issn | 1475-2840 1475-2840 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5282888 |
| source | MEDLINE; Springer Online Journals Complete; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central; Springer Nature OA/Free Journals |
| subjects | Aged Biomarkers - blood Cardiovascular Diseases - blood Cardiovascular Diseases - diagnosis Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control Complications and side effects Cross-Sectional Studies Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - epidemiology Diabetes Mellitus, Type 2 - prevention & control Female Germany - epidemiology Health aspects Humans Incidence Inflammation Interleukin-22 Interleukins Interleukins - blood Linear Models Male Metabolic Syndrome - blood Metabolic Syndrome - diagnosis Metabolic Syndrome - epidemiology Metabolic Syndrome - prevention & control Middle Aged Multivariate Analysis Odds Ratio Original Investigation Prognosis Prospective Studies Protective Factors Risk Assessment Risk Factors Time Factors Type 2 diabetes Up-Regulation |
| title | Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T18%3A15%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20levels%20of%20interleukin-22,%20cardiometabolic%20risk%20factors%20and%20incident%20type%202%20diabetes:%20KORA%20F4/FF4%20study&rft.jtitle=Cardiovascular%20Diabetology&rft.au=Herder,%20Christian&rft.date=2017-01-31&rft.volume=16&rft.issue=1&rft.spage=17&rft.pages=17-&rft.artnum=17&rft.issn=1475-2840&rft.eissn=1475-2840&rft_id=info:doi/10.1186/s12933-017-0498-6&rft_dat=%3Cgale_pubme%3EA480548092%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1864845947&rft_id=info:pmid/28143481&rft_galeid=A480548092&rfr_iscdi=true |